Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis

Eric L. Simpson(Oregon Health & Science University), Abhijit Gadkari(Regeneron (United States)), Laurent Eckert(Sanofi (France)), Ashish Bansal(Regeneron (United States)), Matthew Reaney(Sanofi (United Kingdom)), Shanshan Qin(RTI Health Solutions), Lauren Nelson(RTI Health Solutions), Isabelle Guillemin, Diane Whalley(RTI Health Solutions), Zhen Chen(The First People's Hospital of Shunde), Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases)
Dermatology and Therapy
October 22, 2019
10.1007/s13555-019-00333-2
Cited by 34

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
|Journal of the American Academy of Dermatology|2016|564
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516